TuisAXGN • NASDAQ
AxoGen, Inc Common Stock
$13,79
Na ure:
$13,79
(0,00%)0,00
Toe: 27 Sep., 16:51:46 GMT-4 · USD · NASDAQ · Vrywaring
AandeelVSA-gelyste effekHoofkantoor in VSA
Vorige sluiting
$13,80
Dagwisseling
$13,58 - $14,06
Jaarwisseling
$3,45 - $15,08
Markkapitalisasie
604,41 m USD
Gemiddelde volume
428,84 k
P/V-verhouding
-
Dividend-opbrengs
-
Primêre beurs
NASDAQ
Marknuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
(USD)Jun. 2024J/J-verandering
Inkomste
47,91 m25,57%
Bedryfskoste
35,77 m-2,14%
Netto inkomste
-1,92 m71,16%
Netto winsgrens
-4,0177,03%
Wins per aandeel
0,05266,67%
EBITDA
1,30 m121,63%
Effektiewe belastingkoers
——
Totale bates
Totale aanspreeklikheid
(USD)Jun. 2024J/J-verandering
Kontant en korttermynbeleggings
21,13 m-38,80%
Totale bates
188,93 m-1,41%
Totale aanspreeklikheid
93,24 m-1,32%
Totale ekwiteit
95,69 m—
Uitstaande aandele
43,83 m—
Prys om te bespreek
6,33—
Opbrengs op bates
-0,57%—
Opbrengs op kapitaal
-0,64%—
Netto kontantverandering
(USD)Jun. 2024J/J-verandering
Netto inkomste
-1,92 m71,16%
Kontant van bedrywe
4,16 m1 326,37%
Kontant van beleggings
-1,23 m-108,61%
Kontant van finansiering
544,00 k-39,42%
Netto kontantverandering
3,48 m-77,59%
Beskikbare kontantvloei
3,60 m777,62%
Meer oor
Axogen is a developer of surgical solutions, including human tissue grafts, based in Alachua, Florida. Axogen products are designed to remedy peripheral nerve damage. In 2013 the company raised $18 million in its initial public offering. Axogen uses a cell graft technology AVANCE to mimic a human nerve. The company also creates nerve connectors and soft tissue membranes. The company reports sensory and movement recovery in 87 percent of patients with peripheral nerve injuries. Axogen is part of the Sid Martin Biotechnology Incubator. As of 2019, Axogen was the only commercially available allograft approved by the Food and Drug Administration for clinical use. Wikipedia
Gestig
2002
Werknemers
427
Search
Vee soektog uit
Maak soekkassie toe
Google-programme
Hoofkieslys